Share on StockTwits
 

Equities researchers at Deutsche Bank reduced their price target on shares of GlaxoSmithKline (LON:GSK) from GBX 1,700 ($27.94) to GBX 1,620 ($26.62) in a research report issued on Thursday, Analyst Ratings News reports. The firm currently has a “hold” rating on the stock. Deutsche Bank’s price target points to a potential upside of 1.38% from the company’s current price.

GlaxoSmithKline (LON:GSK) traded up 1.17% during mid-day trading on Thursday, hitting GBX 1598.00. The stock had a trading volume of 9,059,549 shares. GlaxoSmithKline has a 52-week low of GBX 1430.00 and a 52-week high of GBX 1816.00. The stock’s 50-day moving average is GBX 1602. and its 200-day moving average is GBX 1618.93. The company’s market cap is £76.976 billion.

Other equities research analysts have also recently issued reports about the stock. Analysts at Societe Generale cut their price target on shares of GlaxoSmithKline from GBX 1,960 ($32.21) to GBX 1,950 ($32.05) in a research note to investors on Monday. They now have a “buy” rating on the stock. Separately, analysts at Credit Suisse reiterated an “underperform” rating on shares of GlaxoSmithKline in a research note to investors on Friday, January 31st. They now have a GBX 1,600 ($26.29) price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note to investors on Tuesday, January 28th. They now have a GBX 1,750 ($28.76) price target on the stock. Four analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of GBX 1,718.82 ($28.25).

GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.